These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36301466)

  • 21. Acute detoxification of opioid-addicted patients with naloxone during propofol or methohexital anesthesia: a comparison of withdrawal symptoms, neuroendocrine, metabolic, and cardiovascular patterns.
    Kienbaum P; Scherbaum N; Thürauf N; Michel MC; Gastpar M; Peters J
    Crit Care Med; 2000 Apr; 28(4):969-76. PubMed ID: 10809268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of acute morphine withdrawal on ultrasonic vocalizations in adult rats: unchanged 50-kHz call rate and altered subtype profile.
    Lin YC; Zhao LL; Clarke PBS
    Psychopharmacology (Berl); 2018 Jul; 235(7):1945-1953. PubMed ID: 29663018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid and ultrarapid opioid detoxification techniques.
    O'Connor PG; Kosten TR
    JAMA; 1998 Jan; 279(3):229-34. PubMed ID: 9438745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.
    Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacotherapy II: narcotic and narcotic-antagonists analgesics.
    Gardier RW
    Dent Clin North Am; 1978 Jan; 22(1):125-41. PubMed ID: 23324
    [No Abstract]   [Full Text] [Related]  

  • 26. Fecal microbiota transplantation and antibiotic treatment attenuate naloxone-precipitated opioid withdrawal in morphine-dependent mice.
    Thomaz AC; Iyer V; Woodward TJ; Hohmann AG
    Exp Neurol; 2021 Sep; 343():113787. PubMed ID: 34153321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ultrarapid opiate detoxification.
    Bulthuis D; Díaz JE
    Ann Emerg Med; 2000 Jan; 35(1):100-1. PubMed ID: 10613955
    [No Abstract]   [Full Text] [Related]  

  • 29. Increased elevated plus maze open-arm time in mice during naloxone-precipitated morphine withdrawal.
    Hodgson SR; Hofford RS; Norris CJ; Eitan S
    Behav Pharmacol; 2008 Dec; 19(8):805-11. PubMed ID: 19020415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Formulation of Sustained Release Naloxone Can Reverse Opioid Induced Constipation Without Compromising the Desired Opioid Effects.
    Sanders M; Jones S; Löwenstein O; Jansen JP; Miles H; Simpson K
    Pain Med; 2015 Aug; 16(8):1540-50. PubMed ID: 26110375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Naloxone methiodide reverses opioid-induced respiratory depression and analgesia without withdrawal.
    Lewanowitsch T; Irvine RJ
    Eur J Pharmacol; 2002 Jun; 445(1-2):61-7. PubMed ID: 12065195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Caution with naloxone use in asthmatic patients.
    Allegretti PJ; Bzdusek JS; Leonard J
    Am J Emerg Med; 2006 Jul; 24(4):515-6. PubMed ID: 16787825
    [No Abstract]   [Full Text] [Related]  

  • 33. Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.
    Ziedonis DM; Amass L; Steinberg M; Woody G; Krejci J; Annon JJ; Cohen AJ; Waite-O'Brien N; Stine SM; McCarty D; Reid MS; Brown LS; Maslansky R; Winhusen T; Babcock D; Brigham G; Muir J; Orr D; Buchan BJ; Horton T; Ling W
    Drug Alcohol Depend; 2009 Jan; 99(1-3):28-36. PubMed ID: 18805656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of 64 cases with compound diphenoxylate poisoning with naloxone].
    Sun AL; Wang YL
    Zhonghua Er Ke Za Zhi; 2004 Sep; 42(9):716-7. PubMed ID: 15482681
    [No Abstract]   [Full Text] [Related]  

  • 35. Interference with withdrawal signs of naloxone-induced opiate withdrawal under anesthesia is anesthetic-specific in opiate-dependent rats.
    Streel E; Dan B; Bredas P; Clement B; Pelc I; Verbanck P
    Life Sci; 2001 Dec; 70(5):517-22. PubMed ID: 11811896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders.
    Abdelal R; Raja Banerjee A; Carlberg-Racich S; Darwaza N; Ito D; Shoaff J; Epstein J
    Harm Reduct J; 2022 May; 19(1):49. PubMed ID: 35596213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of opioidergic system on mecamylamine-precipitated nicotine-withdrawal aversion in rats.
    Ise Y; Narita M; Nagase H; Suzuki T
    Psychopharmacology (Berl); 2000 Jul; 151(1):49-54. PubMed ID: 10958116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of kratom dependence with buprenorphine/naloxone in a veteran population.
    Lei J; Butz A; Valentino N
    Subst Abus; 2021; 42(4):497-502. PubMed ID: 33617752
    [No Abstract]   [Full Text] [Related]  

  • 39. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
    McCambridge J; Gossop M; Beswick T; Best D; Bearn J; Rees S; Strang J
    Drug Alcohol Depend; 2007 Apr; 88(1):91-5. PubMed ID: 17064857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
    Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
    Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.